Anixa Biosciences, Inc.
Pamela Garzone, Ph.D. is currently serving in various leadership roles in the field of biopharmaceuticals, including as an Independent Director on the Board of Directors at Cue Biopharma. With a strong background in clinical development and pharmacy practice, Pamela has held senior positions at companies like Pfizer Pharmaceuticals and Elan Pharmaceuticals. Pamela also serves as a Chief Development Officer at Anixa Biosciences, Inc. and has a Ph.D. in Clinical Sciences from the University of Pittsburgh, along with other degrees in pharmacy practice, management, and administration.
This person is not in any teams
Anixa Biosciences, Inc.
Anixa Biosciences (NASDAQ:ANIX) is a clinical stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer--specifically triple negative breast cancer (TNBC), the most lethal form of the disease--as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.